In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression

Hepatology

Volumn 54, Issue 1, 2011, Pages 252-261

  Park, Ogyi ^a   Wang, Hua ^a   Weng, Honglei ^c   Feigenbaum, Lionel ^d   Li, Hai ^e   Yin, Shi ^a   Ki, Sung Hwan ^a,f   Yoo, Seong Ho ^b   Dooley, Steven ^c   Wang, Fu Sheng ^c   Young, Howard A ^a   Gao, Bin ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e BEIJING 302 HOSPITAL   (China)

^f Chosun University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIOXIDANT; CONCANAVALIN A; INTERLEUKIN 22;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE COURSE; HEPATITIS; HUMAN; IN VIVO STUDY; LIVER CANCER; LIVER DISEASE; LIVER REGENERATION; MICROARRAY ANALYSIS; MITOGENESIS; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL HEPATITIS; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE;

ANIMALS; CELL SURVIVAL; CONCANAVALIN A; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG-INDUCED LIVER INJURY, CHRONIC; HEPATECTOMY; HEPATITIS B; HEPATITIS C; HUMANS; INTERLEUKINS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; LIVER REGENERATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 79955776494     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24339     Document Type: Article

References (27)

1. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000; 164: 1814-1819.
2. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2010; 32: 17-31.
3. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-467.
4. Witte E, Witte K, Warszawska K, Sabat R, Wolk K. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 2010; 21: 365-379.
5. Lafdil F, Miller AM, Ki SH, Gao B. Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol 2010; 7: 250-254.
6. Trivella DB, Ferreira-Junior JR, Dumoutier L, Renauld JC, Polikarpov I. Structure and function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci 2010; 67: 2909-2935.
7. Aujla SJ, Kolls JK. IL-22: a critical mediator in mucosal host defense. J Mol Med 2009; 87: 451-454.
8. Zenewicz LA, Flavell RA. IL-22 and inflammation: leukin' through a glass onion. Eur J Immunol 2008; 38: 3265-3268.
9. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008; 118: 597-607.
10. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005; 52: 1037-1046.
11. Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K, et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol 2007; 178: 5973-5981.
12. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. HEPATOLOGY 2004; 39: 1332-1342.
13. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647-659.
14. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. HEPATOLOGY 2010; 52: 1291-1300.
15. Yang L, Zhang Y, Wang L, Fan F, Zhu L, Li Z, et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol 2010; 53: 339-347.
16. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947-957.
17. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534-544.
18. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009; 87: 523-536.
19. Savan R, McFarland AP, Reynolds DA, Feigenbaum L, Ramakrishnan K, Karwan M, et al. A novel role for IL-22R1 as a driver of inflammation. Blood 2011; 117: 575-584.
20. Liang SC, Nickerson-Nutter C, Pittman DD, Carrier Y, Goodwin DG, Shields KM, et al. IL-22 induces an acute-phase response. J Immunol 2010; 185: 5531-5538.
21. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124.
22. Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, Tian Z, et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 2002; 110: 1503-1513.
23. Dambacher J, Beigel F, Zitzmann K, Heeg MH, Goke B, Diepolder HM, et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 2008; 41: 209-216.
24. Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. HEPATOLOGY 2010; 51: 81-91.
25. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010; 138: 1536-1545.
26. Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010; 138: 325-335.
27. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 2006; 281: 14111-14118.